Recurrent brain tumors undergo unique genetic changes after treatment
When patients are diagnosed with certain brain tumors, one of the biggest unanswered questions is what happens when…
Scientists identify the neuroblastoma cells that signal poor outcomes
Neuroblastoma is the most common solid tumor found outside of the brain in children, yet why some children…
Disrupted circadian rhythms may influence tumor immunity and cancer spread
Epidemiological studies link light at night (LAN), shift work, chronic jet lag (CJL), and core clock gene mutations…
Mini-GRID radiotherapy limits cellular senescence in glioma models
A new research paper was recently published in Volume 18 of Aging, titled “Spatially fractionated mini-GRID radiotherapy differentially…
Simple urine test can accurately diagnose and track bladder cancer
A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System…
New study reveals how VEGF-C amplifies lymphangiogenic signaling
Lymphatic vessels act as the body’s “drainage system,” collecting excess fluid from tissues. When lymphatic drainage is impaired…
An AI-identified biomarker can look accurate and still fail its biggest test
From blood samples to scans and wearables, the review follows what happens after an AI model identifies a…
AI-based model predicts glioblastoma recurrence to guide targeted treatment
A new AI-based model can predict where glioblastoma is most likely to return after initial surgery, potentially giving…
Researchers find how prostate tumors reshape the immune microenvironment
Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown pathway that prostate…
Scientists reveals how cancer-causing p53 mutations remain invisible to the immune system
One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but…
MD Anderson trial challenges local consolidative therapy paradigm in NSCLC
Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or…
FDA clears trial of dual-targeted CAR T-cell therapy for cancer
The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to…